Spots Global Cancer Trial Database for lhrh agonist
Every month we try and update this database with for lhrh agonist cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer | NCT01790126 | Prostate Cancer | ARN-509 LHRH Agonist | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | NCT04961996 | Early Breast Ca... | Giredestrant Endocrine Thera... LHRH Agonist Abemaciclib | 18 Years - | Hoffmann-La Roche | |
| Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations | NCT05498272 | Prostate Cancer BRCA1 Mutation BRCA2 Mutation Prostatic Adeno... High-Risk Cance... | Olaparib LHRH agonist | 18 Years - | Hoosier Cancer Research Network | |
| Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists | NCT02475057 | Prostatic Neopl... Cardiovascular ... | Degarelix (LHRH... LHRH agonist EndoPAT2000 | 18 Years - 90 Years | Rabin Medical Center | |
| Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer | NCT00288080 | Prostate Cancer | Dexamethasone Prednisone docetaxel Oral antiandrog... Radiation thera... LHRH agonist | 18 Years - 120 Years | Radiation Therapy Oncology Group | |
| The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer | NCT01790126 | Prostate Cancer | ARN-509 LHRH Agonist | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | NCT05296798 | Locally Advance... | Phesgo Giredestrant Docetaxel Paclitaxel LHRH Agonist Optional Endocr... | 18 Years - | Hoffmann-La Roche | |
| A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | NCT01823835 | Breast Cancer | GDC-0810 LHRH Agonist Palbociclib | 18 Years - | Genentech, Inc. | |
| A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) | NCT04546009 | Estrogen Recept... | Giredestrant Giredestrant-ma... Letrozole Letrozole-match... Palbociclib LHRH Agonist | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | NCT05296798 | Locally Advance... | Phesgo Giredestrant Docetaxel Paclitaxel LHRH Agonist Optional Endocr... | 18 Years - | Hoffmann-La Roche | |
| Prostate Boost Irradiation With Stereotactic Body RT (SBRT) | NCT03380806 | Prostate Cancer | LHRH agonist Pelvic Radiatio... Stereotactic Bo... Conventional Ra... | 18 Years - 85 Years | Juravinski Cancer Center | |
| Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer | NCT00005044 | Prostate Cancer | Casodex Eulexin LHRH agonist radiation thera... | 18 Years - 120 Years | Radiation Therapy Oncology Group | |
| Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer | NCT00288080 | Prostate Cancer | Dexamethasone Prednisone docetaxel Oral antiandrog... Radiation thera... LHRH agonist | 18 Years - 120 Years | Radiation Therapy Oncology Group | |
| TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer | NCT06001762 | Breast Cancer Early-stage Bre... High Risk Breas... | Abemaciclib Tamoxifen Anastrozole Letrozole Exemestane LHRH Agonist | 18 Years - | Dana-Farber Cancer Institute | |
| Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy | NCT00528866 | Prostate Cancer | bicalutamide docetaxel flutamide LHRH agonist 3-dimensional c... radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer | NCT00567580 | Prostate Cancer | PBRT PLNRT AA LHRH agonist | 18 Years - | Radiation Therapy Oncology Group | |
| Degarelix Neo-Adjuvant Radical Prostatectomy Trial | NCT01674270 | Prostate Cancer | Degarelix Casodex LHRH Agonist | 18 Years - 75 Years | University Health Network, Toronto | |
| Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer | NCT03879577 | Breast Cancer Breast Cancer F... HER2-positive B... Breast Cancer S... Breast Cancer S... | Docetaxel Herceptin FEC Tamoxifen Letrozole LHRH agonist | 18 Years - 70 Years | University of Chicago | |
| Prostate Boost Irradiation With Stereotactic Body RT (SBRT) | NCT03380806 | Prostate Cancer | LHRH agonist Pelvic Radiatio... Stereotactic Bo... Conventional Ra... | 18 Years - 85 Years | Juravinski Cancer Center | |
| Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer | NCT00567580 | Prostate Cancer | PBRT PLNRT AA LHRH agonist | 18 Years - | Radiation Therapy Oncology Group | |
| Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer | NCT00005044 | Prostate Cancer | Casodex Eulexin LHRH agonist radiation thera... | 18 Years - 120 Years | Radiation Therapy Oncology Group | |
| Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy | NCT00329043 | Prostate Cancer | LHRH Agonist Sunitinib Malat... Radical Prostat... | - | M.D. Anderson Cancer Center | |
| Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy | NCT00329043 | Prostate Cancer | LHRH Agonist Sunitinib Malat... Radical Prostat... | - | M.D. Anderson Cancer Center | |
| Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | NCT05891093 | Breast Cancer | Fluzoparib Anastrozole Letrozole Exemestane Tamoxifen Toremifene Abemaciclib LHRH agonist | 18 Years - 70 Years | Fudan University | |
| A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) | NCT05306340 | Estrogen Recept... | Giredestrant Exemestane Fulvestrant Tamoxifen Everolimus LHRH Agonist Dexamethasone M... | 18 Years - | Genentech, Inc. | |
| A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) | NCT05306340 | Estrogen Recept... | Giredestrant Exemestane Fulvestrant Tamoxifen Everolimus LHRH Agonist Dexamethasone M... | 18 Years - | Genentech, Inc. | |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | NCT06065748 | Estrogen Recept... | Giredestrant Fulvestrant Abemaciclib Palbociclib Ribociclib LHRH Agonist FoundationOne L... | 18 Years - | Hoffmann-La Roche | |
| A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer | NCT03332797 | Breast Cancer | GDC-9545 Palbociclib LHRH Agonist | 18 Years - | Genentech, Inc. | |
| Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer | NCT00288080 | Prostate Cancer | Dexamethasone Prednisone docetaxel Oral antiandrog... Radiation thera... LHRH agonist | 18 Years - 120 Years | Radiation Therapy Oncology Group | |
| A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | NCT01823835 | Breast Cancer | GDC-0810 LHRH Agonist Palbociclib | 18 Years - | Genentech, Inc. | |
| Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer | NCT03058939 | Breast Cancer Breast Cancer S... Breast Cancer S... | Paclitaxel Perjeta Herceptin SC Tamoxifen Letrozole LHRH agonist FEC Carboplatin | 18 Years - 70 Years | University of Chicago | |
| A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | NCT04961996 | Early Breast Ca... | Giredestrant Endocrine Thera... LHRH Agonist Abemaciclib | 18 Years - | Hoffmann-La Roche | |
| Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer | NCT00430183 | Prostate Cancer | docetaxel LHRH agonist surgery | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer | NCT00006359 | Prostate Cancer | LHRH agonist antiandrogen radiation thera... Brachytherapy b... | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
